New York, Oct. 6 - Topigen Pharmaceuticals Inc. said it raised C$6 million in the second closing of its series B financing round, raising the total series B amount to C$28.6 million.
Caisse de depot et placement du Quebec was the investor.
In addition to Caisse, Topigen's venture investors include Desjardins Venture Capital, Fonds de solidarite FTQ, Lothian Partners 27 SARL, T2C2/Bio 2000 and Business Development Bank of Canada.
Topigen, based in Montreal and Randolph, N.J., is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based on DNA and RNA chemistry. The drugs are intended to inhibit multiple inflammatory pathways at the cellular site of inflammation using a single product.
| Issuer: | Topigen Pharmaceuticals Inc.
|
| Issue: | Series B financing
|
| Amount: | C$6 million (total for round: C$28.6 million)
|
| Investor: | Caisse de depot et placement du Quebec
|
| Announcement date: | Oct. 6
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
